Section 3715.052 - Submission of information regarding non-prescription sales of pseudoephedrine or ephedrine productsThe duty to comply with this section is subject to the conditions specified in section 3715.053 of the Revised Code.
(A)(1) Beginning June 1, 2013, a retailer or terminal distributor of dangerous drugs shall submit the following information to the national precursor log exchange regarding each sale of pseudoephedrine product or ephedrine product that is not made pursuant to a valid prescription: (a) The purchaser's name and address;(b) The name and quantity of the product purchased;(c) The date and time of the purchase;(d) The type of government-issued identification provided by the purchaser at the time of purchase, pursuant to division (B)(2) of section 3715.051 of the Revised Code, the identification number, if any, on the identification, and the agency that issued the identification.(2) A retailer or terminal distributor of dangerous drugs that is unable to complete an information submission required by division (A)(1) of this section due to experiencing mechanical or electronic failure of the equipment used to complete the information submission or due to the temporary inability of the retailer or terminal distributor to obtain internet service shall do both of the following: (a) Maintain a written or electronic record of the information in division (A)(1) of this section;(b) Complete the information submission as soon as practicable after the mechanical or electronic failure has been rectified or internet service has been restored.(B)(1) Except as provided in division (B)(2) of this section, a retailer or terminal distributor of dangerous drugs shall not complete a sale if the exchange generates a stop-sale alert after the information is submitted under division (A)(1) of this section.(2) A retailer or terminal distributor of dangerous drugs may complete a sale even though the exchange has generated a stop-sale alert if the retailer or terminal distributor of dangerous drugs has a reasonable fear of imminent bodily harm should the sale not be completed. To accommodate such circumstances, the retailer or terminal distributor of dangerous drugs shall ensure that the override function of the exchange has been enabled.Added by 129th General Assembly, HB 334, §1, eff. 3/20/2013.